Wantstats
Company ProfilePremium

FERRING B.V.

Company Profile Analysis

Book DemoRegister Your Interest
ESOMAR 23 Corporate BadgeISO Certifications Badge
FERRING B.V. - Healthcare showcase

Year Founded & Workforce

1950

6,500 Employees

Industry

Healthcare

Services

MENOPUR (menotropins for injection)ENDOMETRIN (progesterone) Vaginal InsertNOVAREL (chorionic gonadotropin for injection, USP)BRAVELLE (uFSH)CHORAGON (u-HOG)
F

FERRING B.V. Employee Contacts

312 verified contactsNames, job titles, seniority and locations

View Employee Contacts

FERRING B.V. Overview

Company Headquarters: Saint-Prex, Switzerland

Founded: 1950

Workforce: 6500+

Company Working:

Ferring B.V. engages in the R&D, manufacturing, and marketing of a wide range of drugs for osteoarthritis, endocrinology, gastroenterology, urology, obstetrics, and infertility. It provides products and services to private laboratories, clinics, physicians’ offices, and hospitals and critical care centers, through direct sales and a wide network of distributors across the world. It has production centers in 11 countries, including Argentina, the Czech Republic, Denmark, China, Israel, Germany, Mexico, Scotland, and Switzerland. It has R&D centers in China, Denmark, Israel, India, Scotland, Switzerland, and the US. Ferring B.V. has its working subsidiaries in almost 60 nations and markets its treatments in 110 international locations.

Strategy

Ferring focuses to divest activities in some business areas and to strengthen others through portfolio measures, including mergers and acquisitions. Technology and innovations are designed to meet the demand for the requirements of patients with treatment options. It focuses on investing in innovative technology platforms for creating new solutions for patients in their core areas of reproductive medicine and women’s health, gastroenterology, and urology.

Company Snapshot

6,500

Employees

1950

Founded

Saint-Prex, Switzerland

Headquarters

SWOT Analysis

Strengths

  • Strong presence all over the world
  • Diverse product portfolio
  • Strong brand image
  • Innovative products
  • Strong distribution network
  • Well established research & development

Weaknesses

  • Product recalls hampering the company’s growth
  • Increased production costs
  • Low presence in outside Europe
  • Limited products related to the market

Opportunities

  • Expanding the innovation map beyond the established product portfolio
  • Mergers and acquisitions
  • Opportunities to tap emerging markets
  • Merger and acquisitions to expand the portfolio

Threats

  • Demand for products may not increase due to economic conditions
  • Competition from global players
  • Changing competitive environment

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateApproachDevelopment
January 2019AgreementFerring has agreed on terms to acquire the US commercialization rights to produce the Ganirelix Acetate Injection. This injectable therapy is used to prevent premature luteinizing hormone flows in women who are undergoing fertility treatment.
February 2018ExpansionFerring announced the expansion of its capabilities in biologics through the new biotech center installed at the company’s manufacturing site in St-Prex, Switzerland. In addition to the development and manufacture of new biologics, the API for REKOVELLE (for fertility treatment) is also to be manufactured at the new center.
June 2014CollaborationFerring B.V. entered into a collaboration with Roche (Basel, Switzerland), a pioneer in pharmaceuticals and diagnostics, to develop personalized infertility treatment. The collaboration aimed at the combination of diagnostic testing technology from Roche with Ferring’s human cell line-derived recombinant follicle-stimulating hormone (human rFSH), a gonadotropin that was in phase III development.

Product Offering

  • FERRING B.V.
    • MENOPUR (menotropins for injection)
    • ENDOMETRIN (progesterone) Vaginal Insert
    • NOVAREL (chorionic gonadotropin for injection, USP)
    • BRAVELLE (uFSH)
    • CHORAGON (u-HOG)
    • GONAPETYL (triptorelin acetate)
    • LUTINUS (progesterone)
    • LUTREPULSE (gonadorelin acetate)
    • MISODEL (misoprostol vaginal insert)
    • NORPROLAC (quinagolide hydrochloride)
    • REKOVELLE (follitropin delta)
    • Orthopedics

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.

Get Contacts →